Although systemic injection (e.g., i.v.)of AAV-FMRP has not been assessed in rodent models of FXS, translating this to human therapy faces the issues of high peripheral organ uptake of the vector, possible elevated immune reactions, and the very high cost of the large dose that would be required for systemic administration. The gene discussed is FMR1; the disease is fragile X syndrome.